72 results
8-K
EX-99.2
AGIO
Agios Pharmaceuticals Inc
8 Jan 24
Agios Announces Key Anticipated 2024 Milestones Across Rare Disease Portfolio
7:58am
Consortium, BMS / Agios Clinical Trial Sites; top affiliated practices include community and academic heme/onc practices in top 5 deciles; 3+ heme/onc visits … and function PYRUKYND Seamless Phase 2/3 global study designed with community input Potential for mitapivat to: improve anemia reduce sickle cell pain
8-K
EX-99.1
AGIO
Agios Pharmaceuticals Inc
29 Jul 21
Agios Reports Business Highlights and Second Quarter 2021 Financial Results
7:17am
resources and opportunities to connect with other patients and caregivers in the community.
Completed hiring and training of customer-facing
8-K
EX-99.1
AGIO
Agios Pharmaceuticals Inc
16 Nov 18
Agios Presents Updated Data from Phase 1 Dose-Escalation Study ofAG-881 in Patients with IDH Mutant Positive Advanced Glioma
4:01pm
for both ivosidenib andAG-881, along with feedback from regulators and the neuro-oncology community, to make an internal decision on our glioma pivotal
8-K
EX-99.1
AGIO
Agios Pharmaceuticals Inc
1 Dec 20
Other Events
7:46am
and quality of life complications. With only supportive therapy currently available, there is tremendous unmet need in this community, and we are proud
8-K
EX-99.1
08o81famvrt
7 Dec 20
Agios Announces Updated Data from Phase 1 Study of Mitapivat, First-in-Class PKR Activator, in Sickle Cell Disease
4:53pm
8-K
EX-99.1
qphb3bq 3d8jq7tdg3
26 Jan 21
Other Events
4:14pm
8-K
EX-99.1
plm1xr21lf
21 Dec 20
Regulation FD Disclosure
7:04am
DEFA14A
EX-99.1
n9tqgyh8qg ww17m6
21 Dec 20
Additional proxy soliciting materials
7:10am
8-K
EX-99.1
2ds 1bw6af5qd61
8 Dec 14
Agios Announces New Data from Ongoing Phase 1 Trial of AG-221 Showing Robust Clinical Activity in Patients with Advanced Hematologic Malignancies
12:00am
10-Q
0ns5rccacc
5 Sep 13
Quarterly report
12:00am